U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
about
Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World DataLenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.A framework for genomic biomarker actionability and its use in clinical decision makingFludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia.Ginseng alleviates cyclophosphamide-induced hepatotoxicity via reversing disordered homeostasis of glutathione and bile acid.Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaThe constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignanciesRituximab: current status as therapy for malignant and benign hematologic disorders.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
P2860
Q31036587-DF2827FB-EB6C-4151-BF1E-13D45F91A427Q33796183-F9953003-E064-4B2E-86A2-0F2F95963938Q34781122-8E6BB191-9AC3-40EF-A2C5-D94F7DD9A58EQ35806293-405E1AD8-C6C2-4434-90BC-AAF7B8740A1CQ36340043-7DAFCFB3-118D-4312-9780-6E772F2C3BE8Q36490049-28EADF0D-8203-48BB-AD7E-24C90B252AC1Q36529490-66699C7E-5CB0-4491-AAFF-43CB819B30C3Q37984551-970DBBCE-4F9B-4EE3-9368-1D41FFDA60DFQ39018189-32DC909B-EDAE-4A43-8504-18CBBBE2608BQ39279968-BB3FF3CA-AA43-4022-908D-597B5055B642Q51007218-4ED65FF7-1D3E-4E54-B588-ED7BF076C2FE
P2860
U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@ast
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@en
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@nl
type
label
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@ast
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@en
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@nl
prefLabel
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@ast
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@en
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@nl
P2093
P2860
P921
P1433
P1476
U.S. Food and drug administrat ...... chronic lymphocytic leukemia.
@en
P2093
Aakanksha Khandelwal
Gina Davis
Mark D Rothmann
Patricia Keegan
Richard Pazdur
Sandra J Casak
Steven J Lemery
Vaishali Jarral
Yuan Li Shen
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0306
P577
2011-01-06T00:00:00Z